 CONSHOHOCKEN, Pa., June 30, 2021 GLOBE NEWSWIRE -- Madrigal Pharmaceuticals, Inc. NASDAQ:MDGL announced today achievement of the planned target enrollment in the Phase 3 clinical trial, MAESTRO-NASH. Serial liver biopsy and safety data from patients enrolled in MAESTRO-NASH coupled with safety data from MAESTRO-NAFLD-1, an additional large Phase 3 study, are expected to support the planned Subpart H Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses submission to the US Food and Drug Administration FDA. Madrigal will continue to enroll additional patients beyond those required for accelerated approval to provide for the clinical outcomes portion of the MAESTRO-NASH Phase 3 clinical trial of resmetirom. 